Gene Transfer Therapy Fast-Tracked for Duchenne Muscular Dystrophy – Monthly Prescribing Reference

SRP-9001 is designed to deliver the micro-dystrophin-encoding gene to muscle tissue for the targeted production of the micro-dystrophin protein.

 
The Food and Drug Administration (FDA) has granted Fast Track designation to SRP-9001 (AAVrh74.MHCK7.micro-dystrophin; Sarepta Therapeutics) for the treatment of Duchenne muscular dystrophy (DMD).

SRP-9001 is an investigational gene transfer therapy designed to deliver the micro-dystrophin-encoding gene to muscle tissue for the targeted production of the micro-dystrophin protein.

Click here to read full article https://www.empr.com/home/news/drugs-in-the-pipeline/fast-track-gene-transfer-therapy-srp-9001-sarepta-therapeutics-duchenne-muscular-dystrophy/

Share

Leave a Reply

Your email address will not be published. Required fields are marked *

Font Resize